Alpha-2-antiplasmin (a plasmin inhibitor that controls plasmin-mediated fibrinolysis), plasminogen, and tPA concentrations in the blood and urine would be useful markers to be measured also in patients with Fabry disease who are without enzyme replacement therapy and follow their levels after treatment. The gene discussed is PLAT; the disease is Fabry disease.